Anti-ephrin-A4 calicheamicin conjugates, for example, effectively target OC-initiating cells to result in sustained tumor regression [83]; the preclinical data for EC treatment using the antibody drug conjugate MEDI-547 show substantial antitumor activity [85], while the level of EPHA2 expression positively correlates with the therapeutic resistance of CC to epirubicin [69]. Here, EFNA4 is linked to neoplasm.